Supplementary Material to “Identification of microRNA signature in different pediatric brain tumors”

**Figure S4 - Roadmap treatment of HGG.**

<table>
<thead>
<tr>
<th>Course 1</th>
<th>Course 2</th>
<th>Course 3</th>
<th>Course 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>D1</td>
<td>D1</td>
<td>D1</td>
<td>D1</td>
</tr>
<tr>
<td>V</td>
<td>V</td>
<td>V</td>
<td>V</td>
</tr>
<tr>
<td>begin</td>
<td>begin</td>
<td>begin</td>
<td>begin</td>
</tr>
<tr>
<td>next cycle</td>
<td>next cycle</td>
<td>next cycle</td>
<td>next cycle</td>
</tr>
<tr>
<td>Procarbazine</td>
<td>Procarbazine</td>
<td>Procarbazine</td>
<td>Procarbazine</td>
</tr>
</tbody>
</table>

- **Course 5**
  - D1
  - Procarbazine
  - V
  - Begin
  - Next cycle

- **Course 6**
  - D8
  - Procarbazine
  - V
  - *
  - Begin
  - Next cycle

- **Course 7**
  - D8
  - Procarbazine
  - V
  - *
  - Begin
  - Next cycle

- **Course 8**
  - D8
  - Procarbazine
  - V
  - *
  - Begin
  - Next cycle

---

**Notes:**
- *Beginning day 1 of radiation. Etoposide should be started at a dose of 35 mg/m²/day given P.O. in a single daily dose. Therapy will continue for 21 consecutive days (weeks 1-3), followed with a week rest, and restarted for another 21 day (weeks 5-7).**

**Prerequisite prior to each course:**
- CBC (ANC ≥ 1000 / microlitre and Plt ≥ 100,000 / microlitre)
- Liver function tests
- Kidney function tests

**MRI SCAN** Also see Required Observation During Therapy